Loading...
|
Please use this identifier to cite or link to this item:
http://140.128.103.80:8080/handle/310901/22743
|
| Title: | Transdermal nicotine delivery systems: Multi-institutional cooperative bioequivalence studies |
| Authors: | Lin, S., Chien, Y.W., Huang, W.-C., Li, C.-H., Chueh, C.-L., Chen, R.R.-L., Hsu -, T.M., Jiang, T.-S., Wu, J., Valia, K.H. |
| Contributors: | Department of Chemical Engineering, Tunghai University |
| Date: | 1993 |
| Issue Date: | 2013-05-21T09:15:38Z (UTC)
|
| Abstract: | Nicotine transdermal delivery systems (nicotine-TDSs) have been evaluated clinically and found to provide effective assistance to smokers in smoking cessation with minimal occurrence of withdrawal symptoms. However, substantial skin reactions have been reported with the four nicotine-TDSs marketed recently. To reduce the skin reactions, a new type of nicotine-TDS has been recently developed. In vitro skin permeation studies demonstrated that this nicotine-TDS yields a constant skin permeation profile with a rate of permeation across the human cadaver skin comparable to the steady-state permeation rates attained by Habitrol(TM) and Nicoderm? systems. Clinical studies completed in two ethnic groups have demonstrated that this newly- developed nicotine-TDS is clinically effective and has yielded minimal skin irritation. As part of technical transfer program, a clinical study was initiated in 18 non-obese non-smoking Taiwanese, using Latin-square design, to compare the systemic bioavailability and pharmacokinetic profile of nicotine delivered transdermally from the nicotine-TDSs fabricated at technology licensee (Sintong nicotine-TDS) in comparison with that from the technology developer (TBS nicotine-TDS), using one marketed nicotine-TDS (Habitrol(TM) system) as the reference product. In vitro release and skin permeation studies of nicotine from the nicotine-TDSs manufactured at both licensor and licensee were found similar in kinetic profiles and comparable in rates. Since the patch size of these nicotine-TDSs studied was smaller than the marketed product used (10 cm2 for both Sintong and TBS nicotine- TDSs, versus 20 cm2 for Habitrol(TM) system), the daily doses of nicotine delivered to the volunteers are equivalent between Sintong and TBS nicotine- TDSs [9.58 (? 2.23) vs. 8.76 (? 1.88) mg/day/patch] but are lower than that from Habitrol(TM) system [15.13 (? 4.05) mg/day/patch]. Thus, for the statistical analysis of the pharmacokinetic parameters obtained need to be corrected for the difference in patch size and daily nicotine dose delivered. The results of statistical analysis suggested that Sintong and TBS nicotine- TDSs are bioequivalent to Habitrol(TM) system. |
| Relation: | Drug Development and Industrial Pharmacy
Volume 19, Issue 20, 1993, Pages 2765-2793 |
| Appears in Collections: | [化學工程與材料工程學系所] 期刊論文
|
Files in This Item:
| File |
Size | Format | |
|---|
| index.html | 0Kb | HTML | 227 | View/Open |
|
All items in THUIR are protected by copyright, with all rights reserved.
|
